beclomethasone dipropionate
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Trimbow | — | 2017-07-17 | europa.eu ↗ |
| Label expansion | US (FDA) | QNASL | — | 2014-12-17 | fda.gov ↗ |
| Label expansion | US (FDA) | QVAR 80 | — | 2002-05-10 | fda.gov ↗ |
| Label expansion | US (FDA) | VANCENASE | — | 1985-11-02 | fda.gov ↗ |
| Label expansion | US (FDA) | BECONASE | — | 1985-11-01 | fda.gov ↗ |
| Approved | US (FDA) | VANCERIL | — | 1976-05-12 | fda.gov ↗ |
Trials 90 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06139029 | Nov 2022 → Mar 2023 | acute bronchiolitis | Mardan Medical Complex | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT05830071 | Mar → Oct 2023 | asthma, chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT04873063 | Oct 2021 → Apr 2022 | — | SOFAR S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT03859414 | Mar → Jul 2019 | asthma, chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT03795350 | Jan 2019 → Apr 2020 | asthma, chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded |
| Phase 1 | NCT02975843 | Nov 2016 → Mar 2017 | asthma, chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT02030457 | Dec 2013 → Apr 2014 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00936793 | Jul 2009 → Jun 2011 | HIV infectious disease, asthma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT01537692 | Mar → Apr 2009 | allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04817800 | Mar → Apr 2021 | seasonal allergic rhinitis | Humanis | Completed | No outcome recorded |
| Phase 1/2 | NCT01073384 | Dec 2009 → Jan 2012 | enteritis | Soligenix | Completed | No outcome recorded |
| Phase 1/2 | NCT00010283 | Jul 2000 → Jul 2002 | breast cancer, gestational trophoblastic neoplasm, graft versus host disease, kidney cancer +7 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT07301736 | Dec 2025 → Jun 2027 expected | asthma | Chiesi Farmaceutici S.p.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT03590379 | Jun → Oct 2018 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT03084718 | Jul 2017 → Nov 2018 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT03108534 | Feb → Sep 2017 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT02787967 | Aug 2016 → Jun 2017 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT02148120 | Apr → Oct 2014 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT02048644 | Mar 2014 → Apr 2015 | idiopathic pulmonary fibrosis | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT01925950 | Dec 2013 → May 2015 | chronic graft versus host disease | Soligenix | Terminated | No outcome recorded |
| Phase 2 | NCT01738087 | Nov 2012 → Jan 2013 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01544634 | Apr 2012 → May 2013 | asthma | University of Dundee | Completed | No outcome recorded |
| Phase 2 | NCT01650441 | Apr 2012 → Jun 2013 | asthma | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 2 | NCT01468272 | Nov 2011 → Aug 2012 | childhood onset asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01349257 | May → Jun 2011 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01191424 | Oct 2010 → Sep 2011 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00854360 | Mar → May 2009 | seasonal allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01343745 | Feb → Aug 2008 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00489203 | Apr 2007 → Nov 2010 | Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, acute myeloid leukemia with 11q23 abnormalities +27 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00115089 | Jul → Sep 2005 | seasonal allergic rhinitis | Rigel Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00000752 | ? → Feb 1993 | HIV infectious disease, sinusitis | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 341 trials | ||||||
| Phase 3 | NCT04876677 | May 2021 → Jan 2022 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT03562949 | Dec 2018 → Aug 2019 | asthma | Amneal Ireland Limited | Terminated | No outcome recorded |
| Phase 3 | NCT03888131 | Jul 2018 → May 2022 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT03268226 | Nov 2017 → Jan 2019 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT03453112 | Oct 2017 → Dec 2021 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT03197818 | Dec 2016 → May 2020 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT02513160 | Sep 2015 → Mar 2016 | chronic asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02467452 | May 2015 → Jan 2017 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT01658891 | Feb 2014 → Nov 2015 | childhood onset asthma | Chiesi Farmaceutici S.p.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01911364 | Jan 2014 → Mar 2016 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT02040779 | Dec 2013 → Dec 2014 | chronic asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02031640 | Dec 2013 → Nov 2014 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01691677 | Jan 2013 → Jan 2014 | sinusitis | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT01783548 | Jan → Oct 2013 | allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01697956 | Oct 2012 → Feb 2013 | allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01450774 | Sep 2011 → Nov 2013 | childhood onset asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT01351792 | Sep 2011 → Nov 2012 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded |
| Phase 3 | NCT01345916 | Mar → Aug 2011 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT01307319 | Mar → Jul 2011 | seasonal allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01204034 | Sep 2010 → Mar 2012 | chronic obstructive pulmonary disease | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 3 | NCT01133626 | Jun → Sep 2010 | perennial allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01134705 | May → Oct 2010 | perennial allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01113489 | Apr → Jul 2010 | allergic rhinitis, asthma | Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy | Completed | No outcome recorded |
| Phase 3 | NCT00938353 | Apr → Sep 2010 | croup | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded |
| Phase 3 | NCT01024608 | Dec 2009 → Feb 2010 | seasonal allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00988247 | Oct 2009 → Feb 2011 | perennial allergic rhinitis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00926575 | Oct 2009 → Dec 2011 | acute graft versus host disease | Soligenix | Terminated | No outcome recorded |
| Phase 3 | NCT00929851 | Oct 2009 → Mar 2012 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00862394 | Feb → Oct 2009 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00565266 | May 2008 → May 2010 | asthma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00528723 | Nov 2007 → Jan 2009 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00394329 | Nov 2006 → Dec 2011 | asthma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00346775 | May → Jun 2006 | perennial allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00497523 | Mar 2006 → Jan 2007 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00394368 | Nov 2004 → Sep 2005 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00094016 | Oct 2004 → Jun 2006 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00413387 | Sep 2004 → Aug 2005 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00862264 | Aug 2004 → Sep 2005 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00109668 | Jul 2004 → Sep 2006 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00043147 | Apr 2002 → Jan 2005 | graft versus host disease | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00233896 | Jul 2001 → Dec 2004 | graft versus host disease | Enteron Pharmaceuticals | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT06970080 | Jun 2025 → Jun 2028 expected | asthma | McMaster University | Recruiting | No outcome recorded |
| Phase 4 | NCT03141424 | Jun 2022 → Oct 2024 | asthma | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02646904 | May 2016 → Jun 2017 | allergic rhinitis | Stefania La Grutta, MD | Completed | No outcome recorded |
| Phase 4 | NCT02381158 | Feb → Dec 2015 | asthma | Istituto per la Ricerca e l'Innovazione Biomedica | Completed | No outcome recorded |
| Phase 4 | NCT02294279 | May 2014 → Aug 2016 | asthma | Research in Real-Life Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01620099 | Nov 2011 → Apr 2014 | asthma | Università degli Studi di Ferrara | Completed | No outcome recorded |
| Phase 4 | NCT00921921 | Jun 2009 → Oct 2011 | chronic obstructive pulmonary disease | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT00901368 | May 2009 → Sep 2010 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 4 | NCT00910793 | Aug 2008 → Aug 2010 | asthma | Wilfried De Backer | Completed | No outcome recorded |
| Phase 4 | NCT00250341 | Sep 2005 → Sep 2007 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00071552 | Jan 2004 → Jul 2006 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07232264 | Mar → Sep 2025 | asthma | Bugra Kerget | Completed | No outcome recorded |
| — | NCT05888350 | Apr 2023 → Apr 2025 | — | The First Affiliated Hospital of Guangzhou Medical University | Completed | No outcome recorded |
| — | NCT05495698 | Dec 2022 → Dec 2026 expected | chronic obstructive pulmonary disease | Franciscus Gasthuis | Recruiting | No outcome recorded |
| — | NCT01142947 | Oct 2007 → Feb 2017 | asthma | Henry Ford Health System | Completed | No outcome recorded |
| — | NCT03503994 | Jul 2001 → Nov 2006 | bronchopulmonary dysplasia | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| — | NCT00055666 | Mar 2001 → Feb 2005 | graft versus host disease | Roswell Park Cancer Institute | Completed | No outcome recorded |
| — | NCT00238082 | Nov 1999 → Feb 2005 | chronic obstructive pulmonary disease | National Jewish Health | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 31 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05898984 Comparator | Apr → Jul 2023 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT02287272 Comparator | May → Jul 2014 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT01016223 Comparator | Mar 2010 → Jul 2012 | eosinophilic esophagitis | Penn State University | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT02296411 Background | Nov 2014 → Aug 2015 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT02000609 Comparator | Dec 2013 → Apr 2014 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01615874 Comparator | Jan → Sep 2013 | asthma | Organon and Co | Withdrawn | No outcome recorded |
| Phase 2 | NCT01803087 Comparator | Feb → Oct 2012 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01584492 Comparator | Dec 2011 → Feb 2013 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01848769 Comparator | Sep 2009 → Dec 2010 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00868023 Comparator | Feb → Jul 2009 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT05292586 Comparator | Aug 2022 → Jun 2024 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT04320342 Background | Apr 2022 → Jan 2026 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT04886999 Background | Feb 2022 → Feb 2023 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT02676089 Comparator | Apr 2016 → May 2018 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT02676076 Background | Feb 2016 → May 2018 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT02139644 Background | Jun 2014 → Sep 2015 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02040766 Comparator | Dec 2013 → Feb 2016 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01577082 Comparator | Apr → Nov 2012 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT01475032 Comparator | Sep 2011 → Sep 2012 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00476268 Comparator | Feb 2004 → Jan 2005 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT03879772 Comparator | Mar → Jul 1996 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03855189 Comparator | Aug → Oct 1993 | seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07666490 Comparator | Jun 2026 → Jun 2028 expected | asthma | Chiesi Farmaceutici S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06869382 Background | Jan → Dec 2023 | asthma | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | Completed | No outcome recorded |
| Phase 4 | NCT04737655 Comparator | Feb 2021 → Feb 2023 | chronic obstructive pulmonary disease | PARZIBUT Gilles | Unknown | No outcome recorded |
| Phase 4 | NCT03842904 Comparator | Dec 2018 → Jul 2019 | chronic obstructive pulmonary disease | Medicines Evaluation Unit Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02995733 Comparator | Nov 2017 → Apr 2021 | asthma | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01852513 Comparator | Jan → Nov 2013 | seasonal allergic rhinitis | University of Chicago | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02509299 Background | Sep → Nov 2019 | chronic obstructive pulmonary disease | University of Granada | Completed | No outcome recorded |
| — | NCT03408847 Background | Nov 2017 → Dec 2018 | ulcerative colitis | Casa Sollievo della Sofferenza IRCCS | Unknown | No outcome recorded |
| — | NCT02515318 Comparator | Sep 2015 → Mar 2017 | chronic obstructive pulmonary disease | University of Granada | Unknown | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-02-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol tevapharm.com ↗ |
| 2017-08-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Approval of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol tevapharm.com ↗ |
| 2014-12-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis tevapharm.com ↗ |
| 2014-11-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Presents Positive Safety and Efficacy Data for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis tevapharm.com ↗ |
| 2014-05-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Received FDA Approval for QVAR® (beclomethasone dipropionate HFA) with Dose Counter tevapharm.com ↗ |
| 2014-05-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Acceptance of sNDA Filing for Pediatric Indication for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol tevapharm.com ↗ |
| 2013-02-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Additional QNASL® (beclomethasone dipropionate) Nasal Aerosol Data to be Presented at Annual Allergy Meeting tevapharm.com ↗ |
| 2012-11-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase III Data for Teva’s QNASL® (beclomethasone dipropionate) Demonstrate Efficacy Profile in Pediatric Patients with Seasonal Allergic Rhinitis tevapharm.com ↗ |
| 2012-03-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Approval of QNASLTM (beclomethasone dipropionate), a New Nonaqueous Nasal Aerosol, for the Treatment of Allergic Rhinitis tevapharm.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 135 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beclomethasone Dipropionate | “Patients in the MDI group received Foster® metered-dose inhaler (MDI) containing beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg per actuation, administered as...” NCT07232264 ↗83“Beclomethasone dipropionate (BDP) is an anti-inflammatory corticosteroid that is rapidly metabolized to the pharmacologically active monoester, beclomethasone-17-monopropionate...” PMID 22621776 ↗ May 2012 “free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).” NCT01468272 ↗ “Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.” NCT02509299 ↗ “Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) Administered Via Pressurized Metered-dose Inhaler (pMDI)” NCT02467452 ↗ “The fixed combination of extrafine beclomethasone dipropionate and formoterol fumarate (BDP/FF) pMDI (Foster(®)) is approved for treatment of adult asthmatic patients.” PMID 25088067 ↗ Aug 2014 “Beclomethasone dipropionate (BDP) nasal aerosol (non-aqueous) is approved for management of seasonal and perennial allergic rhinitis (PAR) in adolescents and adults.” PMID 26115578 ↗ Jun 2015 “Additional ICS will be delivered as equivalent of hydrofloroalkaline-beclomethasone dipropionate (Qvar) through a metered dose inhaler using an AeroChamber spacer.” NCT06970080 ↗ “The dose-dependent anti-inflammatory effects of a recent fixed combination of extrafine beclomethasone dipropionate/formoterol (BDP/F) were investigated” PMID 22188731 ↗ Dec 2011 “Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).” NCT01351792 ↗ “Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?” NCT00921921 ↗ “Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler” NCT03453112 ↗ “Beclomethasone dipropionate (BDP) hydrofluoroalkane nasal aerosol has been shown to be safe and effective in adolescents and adults with AR.” PMID 24125150 ↗ Aug 2013 “Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide” NCT02515318 ↗ “patient-activated, reliever-triggered inhaled glucocorticoid strategy (beclomethasone dipropionate, 80 μg) plus usual care (intervention)” PMID 35213105 ↗ Feb 2022 “CHF 1535 (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg Dry Powder)” NCT00868023 ↗ “Patients in this group received beclomethasone dipropionate (BDP) HFA pMDI, commonly known as Qvar® pMDI” NCT01577082 ↗ “FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER” NCT01191424 ↗ “Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks” NCT00071552 ↗ “extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI, 2 inhalations BID” PMID 24953015 ↗ Jun 2014 “fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation” NCT01349257 ↗ “Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate 100/6 mcg and 200 mcg” NCT01738087 ↗ “Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD” PMID 33488071 ↗ Jan 2021 “Beclomethasone Dipropionate 250 mcg Plus Salbutamol 100 mcg in HFA pMDI Fixed Combination” NCT00528723 ↗ “extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS” NCT01620099 ↗ “fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg” NCT01450774 ↗ “Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate” NCT00862394 ↗ “treatment with beclomethasone dipropionate (BDP) nasal aerosol” NCT01697956 ↗ “Beclomethasone Dipropionate 50 mcg with Aerochamber Plus” NCT01848769 ↗ “Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg” NCT03562949 ↗ “Beclomethasone Dipropionate (BDP HFA)” NCT01615874 ↗ “BDP (Beclomethasone Dipropionate)” NCT05898984 ↗ “Beclomethasone Dipropionate (BDP)” NCT01475032 ↗ “Beclomethasone Dipropionate (BDP)” NCT03084718 ↗ |
| Known as | BDP | “Beclomethasone dipropionate (BDP) nasal aerosol, a nonaqueous hydrofluoroalkane formulation in a device with a novel integrated dose counter and an established efficacy/safety...” PMID 24169062 ↗ Nov 201330“An extrafine combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) via a pressurised metered-dose inhaler (pMDI) has been commercially available for some...” PMID 28065679 ↗ Jan 2017 “CHF 5993 is an extrafine 'triple therapy' combination of the long-acting muscarinic antagonist glycopyrronium bromide (GB), the long-acting β2-agonist formoterol fumarate (FF),...” PMID 27209586 ↗ Apr 2017 “A single-inhaler extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium (G) has been developed for maintenance therapy of...” PMID 33757520 ↗ Mar 2021 “The hypothesis to be tested is that a topically-active corticosteroid (beclomethasone dipropionate, BDP), taken orally, would allow rapid tapering of prednisone while...” NCT00233896 ↗ “single-inhaler extrafine combination of beclometasone dipropionate (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-acting β2 agonist), and glycopyrronium (G;...” PMID 31582314 ↗ Sep 2019 “A new pediatric fixed combination of beclometasone dipropionate (BDP) 50 μg and formoterol fumarate (FF) 6 μg via pressurized metered-dose inhaler (pMDI) (CHF1535, Chiesi,...” PMID 33404895 ↗ Jan 2021 “Fixed Combination of Beclometasone Dipropionate (BDP) 35 μg Plus Formoterol Fumarate (FF) 4 μg Versus the Free Combination of Licensed BDP DPI (Dry Powder Inhaler) and FF DPI...” NCT02787967 ↗ “Beclomethasone dipropionate (BDP) is an anti-inflammatory corticosteroid that is rapidly metabolized to the pharmacologically active monoester, beclomethasone-17-monopropionate...” PMID 22621776 ↗ May 2012 “Beclomethasone dipropionate (BDP) hydrofluoroalkane nasal aerosol is a recently developed, nonaqueous, nonchlorofluorocarbon formulation of BDP for the treatment of AR.” PMID 23026180 ↗ Sep 2012 “The dose-dependent anti-inflammatory effects of a recent fixed combination of extrafine beclomethasone dipropionate/formoterol (BDP/F) were investigated” PMID 22188731 ↗ Dec 2011 “Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).” NCT01351792 ↗ “The fixed combination of beclomethasone (BDP) and formoterol pressurized metered dose inhaler (pMDI) (Foster®, Chiesi Farmaceutici) is being developed” PMID 22978252 ↗ Apr 2013 “nonaqueous, hydrofluoroalkane-propelled beclomethasone dipropionate (BDP) nasal aerosol was developed and approved for treatment of AR nasal symptoms.” PMID 23815103 ↗ Aug 2013 “Beclomethasone dipropionate (BDP) hydrofluoroalkane nasal aerosol has been shown to be safe and effective in adolescents and adults with AR.” PMID 24125150 ↗ Aug 2013 “Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation.” NCT02040779 ↗ “One of these is the extrafine formulation beclomethasone dipropionate, formoterol fumarate, glycopyrronium bromide (BDP/FF/GB).” PMID 34600734 ↗ Sep 2021 “fixed combination of beclometasone dipropionate (BDP)/formoterol fumarate (FF) in adolescent and adult asthma.” PMID 25808292 ↗ Jun 2015 “Patients in this group received beclomethasone dipropionate (BDP) HFA pMDI, commonly known as Qvar® pMDI” NCT01577082 ↗ “extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI, 2 inhalations BID” PMID 24953015 ↗ Jun 2014 “BDP (Beclometasone Dipropionate)/FF (Formoterol Fumarate)/GB (Glycopyrronium Bromide) 100/6/12.5 µg” NCT07301736 ↗ “400 μg b.i.d. nebulized beclomethasone dipropionate (BDP), plus nebulized 2500 μg prn salbutamol” PMID 21859484 ↗ Aug 2011 “fixed combination of Beclometasone Dipropionate (BDP) 100 µg / Formoterol Fumarate (FF) 6 µg” NCT01191424 ↗ “beclomethasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium (G)” PMID 33488071 ↗ Jan 2021 “Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.” NCT02031640 ↗ “beclomethasone dipropionate (BDP; delivered by breath-actuated inhaler: BAI)” PMID 31047115 ↗ Mar 2019 “fixed dose combination of beclometasone-dipropionate (BDP) and formoterol” PMID 24993817 ↗ Jun 2014 “Beclometasone diproprionate (BDP) 400 μg” NCT02975843 ↗ “Beclomethasone Dipropionate (BDP)” NCT03855189 ↗ “Beclomethasone Dipropionate (BDP)” NCT03084718 ↗ |
| Known as | BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) Nasal Aerosol | “BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) Nasal Aerosol” NCT01307319 ↗ |
| Known as | BDP HFA | “Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.” NCT01307319 ↗ |
| Known as | beclometasone dipropionate | “An extrafine combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) via a pressurised metered-dose inhaler (pMDI) has been commercially available for some...” PMID 28065679 ↗ Jan 201731“Foster is a combination therapy containing beclometasone dipropionate (an inhaled corticosteroid, or ICS) and formoterol fumarate (a long-acting beta-agonist, or LABA), which...” NCT06869382 ↗ “CHF 5993 is an extrafine 'triple therapy' combination of the long-acting muscarinic antagonist glycopyrronium bromide (GB), the long-acting β2-agonist formoterol fumarate (FF),...” PMID 27209586 ↗ Apr 2017 “single-inhaler extrafine combination of beclometasone dipropionate (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-acting β2 agonist), and glycopyrronium (G;...” PMID 31582314 ↗ Sep 2019 “We evaluated the effects of the long acting bronchodilator components of the extrafine single inhaler triple therapy beclometasone dipropionate/formoterol/glycopyrronium...” PMID 33298062 ↗ Dec 2020 “A new pediatric fixed combination of beclometasone dipropionate (BDP) 50 μg and formoterol fumarate (FF) 6 μg via pressurized metered-dose inhaler (pMDI) (CHF1535, Chiesi,...” PMID 33404895 ↗ Jan 2021 “Fixed Combination of Beclometasone Dipropionate (BDP) 35 μg Plus Formoterol Fumarate (FF) 4 μg Versus the Free Combination of Licensed BDP DPI (Dry Powder Inhaler) and FF DPI...” NCT02787967 ↗ “CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)” NCT00901368 ↗ “Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose” NCT03197818 ↗ “fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide” NCT02676089 ↗ “fixed combination of beclometasone dipropionate (BDP)/formoterol fumarate (FF) in adolescent and adult asthma.” PMID 25808292 ↗ Jun 2015 “CHF 1535, a fixed-dose combination of beclometasone dipropionate (100 µg) and formoterol fumarate (6 µg).” NCT03888131 ↗ “beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days” NCT02048644 ↗ “a fixed combination of beclometasone-dipropionate/formoterol-fumarate administered via pMDI with VHC” PMID 24746942 ↗ Apr 2014 “BDP (Beclometasone Dipropionate)/FF (Formoterol Fumarate)/GB (Glycopyrronium Bromide) 100/6/12.5 µg” NCT07301736 ↗ “fixed combination of Beclometasone Dipropionate (BDP) 100 µg / Formoterol Fumarate (FF) 6 µg” NCT01191424 ↗ “CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)” NCT03108534 ↗ “6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol” NCT01204034 ↗ “6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol” NCT00910793 ↗ “beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide” PMID 28385353 ↗ Apr 2017 “fixed dose combination of beclometasone-dipropionate (BDP) and formoterol” PMID 24993817 ↗ Jun 2014 “beclometasone dipropionate /formoterol fumarate/glycopyrronium bromide” NCT05830071 ↗ “beclometasone dipropionate” NCT03141424 ↗ |
| Known as | beclomethasone 17,21-dipropionate | “A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate) Administered as...” NCT01925950 ↗ |
| Known as | Beconase | “The agents being compared are: R926112 (a novel anti-allergy medicine), Beconase (beclomethasone dipropionate, an established FDA approved steroid treatment), and an inactive placebo.” NCT00115089 ↗ |
| Known as | CHF 718 | “CHF 718 pMDI = 100 μg pressurised metered dose inhaler (extrafine beclomethasone dipropionate [BDP]).” NCT05292586 ↗ |
| Known as | CHF 718 pMDI | “CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler)” NCT03084718 ↗ |
| Known as | HFA-BDP | “Beclomethasone Dipropionate (HFA-BDP, QVAR\*) in the following doses will be evaluated:” NCT03503994 ↗ |
| Known as | orBec | “Immediate release tablets and enteric-coated tablets, each contained 1 mg of BDP (orBec, DOR BioPharma, Miami FL).” NCT00233896 ↗ |
| Known as | QNASL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01852513 ↗ |
| Known as | QVAR | “Safety and Efficacy Evaluation of Two Doses of HFA-Propelled Beclomethasone Dipropionate (QVAR) Versus Placebo by Breath Operated and Metered Dose Inhalers in Mild to Moderate...” NCT00094016 ↗13“QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate.” NCT02139644 ↗ “BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)” NCT01803087 ↗ “Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg.” NCT02296411 ↗ “Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks” NCT00071552 ↗ “Beclomethasone Dipropionate (HFA-BDP, QVAR\*) in the following doses will be evaluated:” NCT03503994 ↗ “HFA-134A Beclomethasone DIpropionate (QVAR)” NCT00238082 ↗ “beclomethasone dipropionate (QVAR)” NCT00109668 ↗ “BDP HFA Inhalation Aerosol (QVAR)” NCT01537692 ↗ |
| Known as | QVAR REDIHALER | “BDP HFA (QVAR REDIHALER®, BDP 80 μg)” NCT05898984 ↗ |
| Known as | SGX201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01073384 ↗ |
| Modality | Other / unclassified | “a topically-active corticosteroid (beclomethasone dipropionate, BDP)” NCT00233896 ↗ |
| Route | Intranasal | “anti-inflammatory nasal spray ( beclomethasone dipropionate )” NCT00000752 ↗ |